Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Abeona Therapeutics to announce earnings of ($0.23) per share and revenue of $12.2380 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last announced its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The firm had revenue of $8.72 million during the quarter, compared to analyst estimates of $4.57 million. On average, analysts expect Abeona Therapeutics to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.
Abeona Therapeutics Trading Down 0.7%
NASDAQ:ABEO opened at $7.40 on Wednesday. The stock’s 50 day moving average price is $6.26 and its 200 day moving average price is $5.54. The company has a market capitalization of $421.76 million, a PE ratio of 7.63 and a beta of 1.35. The company has a quick ratio of 5.70, a current ratio of 5.89 and a debt-to-equity ratio of 0.03. Abeona Therapeutics has a 52-week low of $4.00 and a 52-week high of $7.65.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on ABEO
Insider Activity
In related news, Director Christine Berni Silverstein sold 18,160 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $5.71, for a total transaction of $103,693.60. Following the transaction, the director owned 119,562 shares of the company’s stock, valued at $682,699.02. This trade represents a 13.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Joseph Walter Vazzano sold 39,067 shares of the business’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $5.36, for a total value of $209,399.12. Following the completion of the transaction, the chief financial officer owned 518,437 shares in the company, valued at $2,778,822.32. This trade represents a 7.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 307,221 shares of company stock valued at $1,854,494. Insiders own 7.10% of the company’s stock.
Hedge Funds Weigh In On Abeona Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of ABEO. XTX Topco Ltd increased its stake in Abeona Therapeutics by 25.4% in the 4th quarter. XTX Topco Ltd now owns 49,338 shares of the biopharmaceutical company’s stock valued at $260,000 after buying an additional 9,979 shares during the period. Tang Capital Management LLC purchased a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $5,270,000. Balyasny Asset Management L.P. purchased a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $3,118,000. J. Goldman & Co LP acquired a new position in shares of Abeona Therapeutics during the fourth quarter worth about $2,102,000. Finally, AQR Capital Management LLC increased its stake in shares of Abeona Therapeutics by 240.7% during the fourth quarter. AQR Capital Management LLC now owns 114,520 shares of the biopharmaceutical company’s stock worth $604,000 after acquiring an additional 80,908 shares during the period. 80.56% of the stock is currently owned by hedge funds and other institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.
The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Read More
- Five stocks we like better than Abeona Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
